Denali Therapeutics Inc.
Compounds, compositions, and methods
Last updated:
Abstract:
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
Status:
Grant
Type:
Utility
Filling date:
13 Mar 2020
Issue date:
7 Sep 2021